AKT1 and non-small cell lung carcinoma: Fortunately, elevating ROS levels could inhibit IGF1R bypass signaling and ERK/AKT/nuclear factor κB (NF-κB) signal pathways in the downstream, leading to high efficacy in inhibiting cell proliferation and overcoming bypass signal activation–related GEF resistance in NSCLC treatment (13).